COMPLIMENTARY WEBINAR
UNCOVER THE CONNECTION BETWEEN SARS-CoV-2/COVID-19 AND COAGULOPATHY
The unique nature of hemostasis in COVID-19 patients highlights the need for ongoing discussion about optimal infection-related coagulopathy assessment and management.1 

Learning Objectives
As a participant, you will:
  • Examine hemostasis-related pathophysiology models associated with COVID infection
  • Apply diagnostic and prognostic hemostasis laboratory assay results to COVID pathophysiology
  • Align hemostasis laboratory results and pathophysiology with disease progress

Webinar Discussants
  • Moderator: Mr. George A. Fritsma, MS, MLS, coagulation consultant and associate professor, University of Alabama at Birmingham and Michigan State University; coagulation science education leader and Proprietor of The Fritsma Factor, Your Interactive Hemostasis Resource.
  • Presenter: Andrew J. Goodwin, MD, Division Chief for Clinical Laboratory Medicine and the CLIA Medical Director for University of Vermont Medical Center Laboratories.
Title:

´╗┐Date:
Time:
Duration:
Accreditation:
COVID Coag: A Conversation about the Controversies and Confusion
Tuesday, September 15, 2020
5 PM US EDT (GMT: 21:00)
60 minutes
BioMedica Diagnostics Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Reserve your space at this exciting event!
Let your colleagues know about this important educational opportunity by sharing this link: bit.ly/COVID-Coag 
Reference:
1. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemostas. 2020; doi: 10.1111/jth.14929.
This webinar is supported by an educational grant from BioMedica Diagnostics, Inc., a member of the Scotia Investments family of companies.